Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jul;70(1):138–141. doi: 10.1038/bjc.1994.263

Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma.

M Färkkilä 1, J Jääskeläinen 1, M Kallio 1, G Blomstedt 1, R Raininko 1, P Virkkunen 1, A Paetau 1, H Sarelin 1, M Mäntylä 1
PMCID: PMC2033327  PMID: 8018525

Abstract

The effect of intratumoral recombinant interferon gamma (rIFN-gamma) as adjuvant to open cytoreduction and external irradiation of 60 Gy on survival in adults with a newly diagnosed high-grade cerebral glioma was studied. The patients were randomised during surgery into the rIFN-gamma group (n = 14) or the control group (n = 17), and the latter received a subcutaneous reservoir of rIFN-gamma injections. Intratumoral rIFN-gamma was given three times a week for 4 weeks until radiotherapy, escalating the dose from 5 micrograms to 50 micrograms. Both groups received external whole-brain irradiation of 40 Gy and a local boost of 20 Gy. After radiotherapy, rIFN-gamma was continued with 50 micrograms twice a week up to 9 weeks. The patients received no chemotherapy. Intratumoral rIFN-gamma was tolerated well with transient fever only. There were 12 glioblastomas (GBs) in the control group and nine in the rIFN-gamma group with completed irradiation. The patients were followed clinically and by computerised tomography (CT) every third month until death. Tumour responses were seen in three interferon-treated (one still alive 45 months after operation) and in two conventionally treated patients. The progression of the tumour volumes on CT did not differ between the IFN-treated and control groups. There were no differences in the survival times. Median survival of the rIFN-gamma-treated patients was 54 weeks (95% CI 35-68) and of the control patients 55 weeks (95% CI 41-77). Intratumoral rIFN-gamma given in the study doses does not seem to inhibit tumour growth or improve the prognosis of patients with high-grade glioma.

Full text

PDF
138

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J., Packer R., Bleyer A., Zeltzer P., Prados M., Nirenberg A. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol. 1991 May;9(5):783–788. doi: 10.1200/JCO.1991.9.5.783. [DOI] [PubMed] [Google Scholar]
  2. Kallio M. The incidence of intracranial gliomas in southern Finland. Acta Neurol Scand. 1988 Dec;78(6):480–483. doi: 10.1111/j.1600-0404.1988.tb03691.x. [DOI] [PubMed] [Google Scholar]
  3. Lee Y., Bigner D. D. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Neurol Clin. 1985 Nov;3(4):901–917. [PubMed] [Google Scholar]
  4. Maasilta P., Holsti L. R., Halme M., Kivisaari L., Cantell K., Mattson K. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;23(4):863–868. doi: 10.1016/0360-3016(92)90660-a. [DOI] [PubMed] [Google Scholar]
  5. Mahaley M. S., Jr, Gillespie G. Y. New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy. Clin Neurosurg. 1983;31:456–469. doi: 10.1093/neurosurgery/31.cn_suppl_1.456. [DOI] [PubMed] [Google Scholar]
  6. Nagai M., Arai T. Clinical effect of interferon in malignant brain tumours. Neurosurg Rev. 1984;7(1):55–64. doi: 10.1007/BF01743290. [DOI] [PubMed] [Google Scholar]
  7. Nazzaro J. M., Neuwelt E. A. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg. 1990 Sep;73(3):331–344. doi: 10.3171/jns.1990.73.3.0331. [DOI] [PubMed] [Google Scholar]
  8. Roszman T., Elliott L., Brooks W. Modulation of T-cell function by gliomas. Immunol Today. 1991 Oct;12(10):370–374. doi: 10.1016/0167-5699(91)90068-5. [DOI] [PubMed] [Google Scholar]
  9. Shapiro W. R., Green S. B., Burger P. C., Selker R. G., VanGilder J. C., Robertson J. T., Mealey J., Jr, Ransohff J., Mahaley M. S., Jr A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. 1992 May;76(5):772–781. doi: 10.3171/jns.1992.76.5.0772. [DOI] [PubMed] [Google Scholar]
  10. Winger M. J., Macdonald D. R., Schold S. C., Jr, Cairncross J. G. Selection bias in clinical trials of anaplastic glioma. Ann Neurol. 1989 Oct;26(4):531–534. doi: 10.1002/ana.410260406. [DOI] [PubMed] [Google Scholar]
  11. Yung W. K., Prados M., Levin V. A., Fetell M. R., Bennett J., Mahaley M. S., Salcman M., Etcubanas E. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol. 1991 Nov;9(11):1945–1949. doi: 10.1200/JCO.1991.9.11.1945. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES